Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study-Reference-Cited by-同舟云学术

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Published:2024-01 Issue:1 Volume:35 Page:77-90
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Passaro A.^ORCID,Wang J.,Wang Y.,Lee S.-H.,Melosky B.,Shih J.-Y.^ORCID,Wang J.,Azuma K.,Juan-Vidal O.,Cobo M.,Felip E.,Girard N.,Cortot A.B.,Califano R.,Cappuzzo F.,Owen S.,Popat S.^ORCID,Tan J.-L.,Salinas J.,Tomasini P.,Gentzler R.D.^ORCID,William W.N.^ORCID,Reckamp K.L.^ORCID,Takahashi T.,Ganguly S.^ORCID,Kowalski D.M.,Bearz A.^ORCID,MacKean M.,Barala P.,Bourla A.B.^ORCID,Girvin A.,Greger J.,Millington D.,Withelder M.,Xie J.,Sun T.,Shah S.,Diorio B.,Knoblauch R.E.,Bauml J.M.,Campelo R.G.,Cho B.C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference43 articles.

1. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors;Gazdar;Oncogene,2009

2. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer;Vyse;Signal Transduct Target Ther,2019

3. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology;Ettinger;J Natl Compr Canc Netw,2022

4. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up,2020

5. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysis;2024-09-11

2. Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer;Journal of Managed Care & Specialty Pharmacy;2024-09-11

3. Novel Combination of Therapeutic Approaches in Advanced NSCLC with EGFR Activating Mutations;Targets;2024-09-07

4. Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression;npj Precision Oncology;2024-09-06

5. Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?;CLIN LUNG CANCER;2024